doi: 10.1097/01.NAJ.0000742484.81331.b2.
Monoclonal Antibody Approved to Treat Ebola
Affiliations
- PMID: 33755619
- DOI: 10.1097/01.NAJ.0000742484.81331.b2
Item in Clipboard
Monoclonal Antibody Approved to Treat Ebola
Am J Nurs.
.
Abstract
Ansuvimab-zykl (Ebanga), a human monoclonal antibody, has been approved to treat Zaire ebolavirus (Ebolavirus) infection.The most common adverse effects of the drug are fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills; these are also common symptoms of Ebolavirus infection.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Ansuvimab: First Approval.Drugs. 2021 Apr;81(5):595-598. doi: 10.1007/s40265-021-01483-4. Epub 2021 Mar 22. Drugs. 2021. PMID: 33751449 Free PMC article. Review.
-
REGN-EB3: First Approval.Drugs. 2021 Jan;81(1):175-178. doi: 10.1007/s40265-020-01452-3. Drugs. 2021. PMID: 33432551 Free PMC article. Review.
-
Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.Front Immunol. 2021 Aug 30;12:721328. doi: 10.3389/fimmu.2021.721328. eCollection 2021. Front Immunol. 2021. PMID: 34526994 Free PMC article. Review.
-
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471. Sci Transl Med. 2013. PMID: 23785035 Free PMC article.
-
Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020.N Engl J Med. 2022 Mar 24;386(12):1188-1191. doi: 10.1056/NEJMc2113505. N Engl J Med. 2022. PMID: 35320651 No abstract available.
Cited by
-
Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential.PLoS One. 2024 Jul 2;19(7):e0305034. doi: 10.1371/journal.pone.0305034. eCollection 2024. PLoS One. 2024. PMID: 38954719 Free PMC article.
-
Proceedings from the Fourth Mesoamerican Symposium "Dr. Roberto Navarro López" on Emerging Zoonotic Disease and Arboviruses: Commenting Insights and Research Findings.Res Rep Trop Med. 2025 Jul 31;16:65-89. doi: 10.2147/RRTM.S512767. eCollection 2025. Res Rep Trop Med. 2025. PMID: 40771869 Free PMC article.
-
Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.Int J Mol Sci. 2023 Mar 27;24(7):6298. doi: 10.3390/ijms24076298. Int J Mol Sci. 2023. PMID: 37047270 Free PMC article.
-
Evaluation of fendiline treatment in VP40 system with nucleation-elongation process: a computational model of Ebola virus matrix protein assembly.Microbiol Spectr. 2024 Apr 2;12(4):e0309823. doi: 10.1128/spectrum.03098-23. Epub 2024 Feb 26. Microbiol Spectr. 2024. PMID: 38407984 Free PMC article.
-
Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly.J Biol Chem. 2022 Jul;298(7):102025. doi: 10.1016/j.jbc.2022.102025. Epub 2022 May 11. J Biol Chem. 2022. PMID: 35568195 Free PMC article.
References
REFERENCE
-
- Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381(24):2293–303.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
